Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial.
Fiche publication
Date publication
septembre 2016
Journal
BMC immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FOUYSSAC Fanny, Dr OJEDA-URIBE Mario
Tous les auteurs :
Viallard JF, Agape P, Barlogis V, Cozon G, Faure C, Fouyssac F, Gaud C, Gourin MP, Hamidou M, Hoarau C, Husseini F, Ojeda-Uribe M, Pavic M, Pellier I, Perlat A, Schleinitz N, Slama B
Lien Pubmed
Résumé
Although Hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase III trials have focused on patients with primary immunodeficiencies. In this 9-month, real-life, prospective, non-interventional, longitudinal, multicenter study of patients with primary and secondary immunodeficiencies in France, treatment modalities (primary endpoint), efficacy, safety, tolerability, quality of life, and treatment satisfaction were evaluated using descriptive statistics.
Référence
BMC Immunol.. 2016 Sep;17(1):34